{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:03:49Z","timestamp":1790172229157,"version":"4.1.0"},"reference-count":29,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Amgen Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"DOI":"10.1080\/14740338.2026.2735075","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:19:30Z","timestamp":1790169570000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCT"],"prefix":"10.1080","author":[{"given":"Vinicius","family":"Domingues","sequence":"first","affiliation":[{"name":"Florida State University","place":["Tallahassee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Abdellatif","sequence":"additional","affiliation":[{"name":"Nephrology Division","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Woods","sequence":"additional","affiliation":[{"name":"Amgen Inc","place":["Deerfield, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinnie","family":"Yang","sequence":"additional","affiliation":[{"name":"Amgen Inc","place":["Deerfield, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-5512","authenticated-orcid":false,"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Ji","sequence":"additional","affiliation":[{"name":"Amgen Inc","place":["Deerfield, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3204-082X","authenticated-orcid":false,"given":"Brad","family":"Marder","sequence":"additional","affiliation":[{"name":"Amgen Inc","place":["Deerfield, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[{"name":"Amgen Inc","place":["Deerfield, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"2","key":"e_1_3_7_3_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson JK","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75(2):293\u2013304. .","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_7_4_1","unstructured":"Horizon Therapeutics USA Inc. KRYSTEXXA (pegloticase) injection for intravenous use. Package insert. 2022 [cited 2026 June 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125293s104lbl.pdf"},{"key":"e_1_3_7_5_1","volume-title":"StatPearls","author":"Nimmana BK","year":"2026","unstructured":"Nimmana BK, Patel P. Disease-modifying antirheumatic drugs (DMARDs). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"e_1_3_7_6_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/OARRR.S131668","article-title":"Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis","volume":"9","author":"Bello AE","year":"2017","unstructured":"Bello AE, Perkins EL, Jay R, et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67\u201379.","journal-title":"Open Access Rheumatol"},{"issue":"11","key":"e_1_3_7_7_1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert CL","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914\u20131915.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"e_1_3_7_8_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin S","year":"2013","unstructured":"Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444\u2013447.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"e_1_3_7_9_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik AS","year":"2017","unstructured":"Strik AS, van den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128\u20131134.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"e_1_3_7_10_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani M","year":"2014","unstructured":"Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213\u2013222.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"e_1_3_7_11_1","doi-asserted-by":"crossref","first-page":"e001047","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau E","year":"2020","unstructured":"Ducourau E, Rispens T, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6(1):e001047.","journal-title":"RMD Open"},{"key":"e_1_3_7_12_1","unstructured":"EXCELLA GmbH. Methotrexate tablets. Package insert. 2009. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015 s016 s017.pdf"},{"issue":"9","key":"e_1_3_7_13_1","first-page":"e29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed KM","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14(9):e29518.","journal-title":"Cureus"},{"key":"e_1_3_7_14_1","unstructured":"US Food and Drug Administration. Methotrexate tablets for oral use: highlights of prescribing information. Silver Spring MD; 2020 [updated 2025 Oct 20; cited 2026 June 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015 s016 s017.pdf"},{"issue":"1","key":"e_1_3_7_15_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley MJ","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"e_1_3_7_16_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","article-title":"Busting the myth of methotrexate chronic hepatotoxicity","volume":"19","author":"Di Martino V","year":"2023","unstructured":"Di Martino V, Verhoeven DW, Verhoeven F, et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat Rev Rheumatol. 2023;19(2):96\u2013110.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"e_1_3_7_17_1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u20131482.","journal-title":"Oncologist"},{"issue":"9","key":"e_1_3_7_18_1","first-page":"1090","article-title":"Hepatic fibrosis before and during intensive urate-lowering with pegloticase in the presence and absence of methotrexate co-therapy [abstract]","volume":"76","author":"Schlesinger N","year":"2024","unstructured":"Schlesinger N, Obermeyer K, Padnick-Silver L, et al. Hepatic fibrosis before and during intensive urate-lowering with pegloticase in the presence and absence of methotrexate co-therapy [abstract]. Arthritis Rheumatol. 2024;76(suppl 9):1090.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"e_1_3_7_19_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/acr2.11578","article-title":"A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings","volume":"5","author":"Botson JK","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, et al. A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings. ACR Open Rheumatol. 2023;5(8):407\u2013418. .","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"e_1_3_7_20_1","first-page":"1992","article-title":"Tolerance of methotrexate coadministered with pegloticase in patients with uncontrolled gout: findings from MIRROR RCT [abstract]","volume":"77","author":"Domingues V","year":"2025","unstructured":"Domingues V, Woods A, Yang X, et al. Tolerance of methotrexate coadministered with pegloticase in patients with uncontrolled gout: findings from MIRROR RCT [abstract]. Arthritis Rheumatol. 2025;77(suppl 9):1992.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"e_1_3_7_21_1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/acr.23999","article-title":"Low-dose methotrexate and mucocutaneous adverse events: results of a systematic literature review and meta-analysis of randomized controlled trials","volume":"72","author":"Lalani R","year":"2020","unstructured":"Lalani R, Lyu H, Vanni K, et al. Low-dose methotrexate and mucocutaneous adverse events: results of a systematic literature review and meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2020;72(8):1140\u20131146.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"e_1_3_7_22_1","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea B","year":"2013","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"e_1_3_7_23_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000810","article-title":"Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review","volume":"25","author":"Liu L","year":"2019","unstructured":"Liu L, Liu S, Wang C, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2019;25(5):197\u2013202.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"e_1_3_7_24_1","doi-asserted-by":"crossref","first-page":"e37424","DOI":"10.1097\/MD.0000000000037424","article-title":"Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: a retrospective case series","volume":"103","author":"Albert J","year":"2024","unstructured":"Albert J, Broadwell A, Padnick-Silver L, et al. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: a retrospective case series. Medicine (Baltimore). 2024;103(10):e37424.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_7_25_1","doi-asserted-by":"crossref","unstructured":"Stern L Johnson RJ Shakouri P et al. Prevalence and influence of gout in patients with advanced chronic kidney disease: findings of a large retrospective chart review. Gout Urate Cryst Depos Dis. 2024;2(1):77\u201385. .","DOI":"10.3390\/gucdd2010008"},{"key":"e_1_3_7_26_1","doi-asserted-by":"crossref","first-page":"100791","DOI":"10.37349\/emd.2025.100791","article-title":"Management of gout in advanced renal disease","volume":"3","author":"Richards JS","year":"2025","unstructured":"Richards JS, Nair N, Ramkumar M. Management of gout in advanced renal disease. Explor Musculoskelet Dis. 2025;3:100791. .","journal-title":"Explor Musculoskelet Dis"},{"key":"e_1_3_7_27_1","unstructured":"Baltic S. Moderate alcohol use could be safe with methotrexate for RA. The Rheumatologist; 2017 [cited 2026 June 4]. Available from: https:\/\/www.the-rheumatologist.org\/article\/moderate-alcohol-use-safe-methotrexate-ra\/"},{"key":"#cr-split#-e_1_3_7_28_1.1","unstructured":"Centers for Disease Control and Prevention. About standard drink sizes. 2024 [updated 2024 Dec 12"},{"key":"#cr-split#-e_1_3_7_28_1.2","unstructured":"cited 2026 June 2]. Available from: https:\/\/www.cdc.gov\/alcohol\/standard-drink-sizes\/index.html"},{"issue":"9","key":"e_1_3_7_29_1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/annrheumdis-2016-210629","article-title":"Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate","volume":"76","author":"Humphreys JH","year":"2017","unstructured":"Humphreys JH, Warner A, Costello R, et al. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Ann Rheum Dis. 2017;76(9):1509\u20131514.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"e_1_3_7_30_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjmed.2013.12.019","article-title":"Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study","volume":"127","author":"Neogi T","year":"2014","unstructured":"Neogi T, Chen C, Niu J, et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med. 2014;127(4):311\u2013318.","journal-title":"Am J Med"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2026.2735075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14740338.2026.2735075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2026.2735075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:19:39Z","timestamp":1790169579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2026.2735075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"alternative-id":["10.1080\/14740338.2026.2735075"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2026.2735075","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"14740338.2026.2735075"}}